CClinicalTrials.gg
Status unknownNCT01529918Updated Feb 9, 2012

Detecting Diabetes Sooner With a Risk Survey for the Family Doctor:Comparing Internet and Traditional Methods of Communication for Patients and Doctors

An interventional study of CANRISK (Canadian Diabetes Association Assessment) in Diabetes, sponsored by McMaster University. Status unknown. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2012-02-09.

Sponsored by McMaster University · Not applicable, Interventional, and Health services research

The sponsor has not verified this record recently (last verified Oct 2009), so the status shown — last known as Active, not recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
2,000
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Study summary

This pilot RCT study aims to develop and evaluate the uptake, feasibility, and potential value of a strategy for web-diabetes risk assessment versus paper-based methods in an undiagnosed diabetes population over 40 years of age from all listed FHT provided through an electronic medical record database. Following randomization, intervention participants will have the option to decide to use web-based self-screening and the control group will receive only a paper-based method. There will be two options for web-based screening; one involves completion of the CAN-RISK screening tool as part of a personal health record self-management program (MyOscar) versus a one off online risk-assessment. The intervention and control group will be compared with respect to risk-assessment uptake. Educational sessions and further assessment of diabetes conducted by the clinical health care team will be offered to all participants who scored a high risk of diabetes in accordance with the CAN-RISK results. Actual numbers of diabetes cases in those with a high risk score will be compared between the intervention and control groups as well as compared to the usual method of diabetes screening in a randomly chosen non-identifiable sample from the same clinical setting in the same one year period. The assessment of patient acceptability in feasibility of the implementation of the self-screening tool will be accomplished through surveys designed to be completed by patients and staff.

02

Conditions studied

  • Diabetes

Browse trials for

Keywords

  • Diabetes
  • Self-screening
  • Web-based technology
  • follow-up clinical care
  • randomized control trial
03

In context

Diabetes Mellitus

10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.

This study's planned enrollment of 2,000 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.

Browse Diabetes Mellitus studies →

Lead sponsor

McMaster University is the lead sponsor of 720 studies on the registry; 124 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients aged 40 and over who did not have diagnosis of diabetes and no previous use of personal health record (MyOscar)

Exclusion criteria

Exclusion Criteria:

  • People with diabetes, and those who are already registered as MyOSCAR (personal e-health record) users
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,000 participants (estimated)

Study arms

  • Experimental
    web-intervention group

    Participants will receive access to the CAN-RISK (Canadian Diabetes Risk Assessment) questionnaire either via personal patient electronic health record or an online version

    Other: CANRISK (Canadian Diabetes Association Assessment)

  • No intervention
    paper-based group

    Participants allocated to paper-based will receive the CAN-RISK questionnaire for diabetes risk-assessment via paper-based

    Other: CANRISK (Canadian Diabetes Association Assessment)

Interventions

  • OtherCANRISK (Canadian Diabetes Association Assessment)

    Self-risk assessment questionnaire for diabetes

06

What researchers measure

Primary outcomes

  1. Patient's uptake and preferences

    Numbers of patients participating in the self risk-assessment, and a comparison of paper versus web-based technologies will be collected. * Demographics of the 2 groups will be compared. * A user-satisfaction survey will assess patients' perceptions of the technologies. Use of necessary qualitative techniques can be considered as well.

    Time frame: 1 year

Secondary outcomes

  1. The comparison of yield of actual diabetes detected from those who have high risk at self risk-assessment, compared to the usual diabetes detection rate in a random sample from the practice within a one year period.

    Time frame: 1 year

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 9, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01529918
Lead sponsor
McMaster University
Responsible party
Sponsor
First posted
Feb 9, 2012
Start date
Nov 2009
Primary completion
Mar 2012 (estimated)
Completion
Mar 2012 (estimated)
Last update
Feb 9, 2012

Study contacts

Gina Agarwal, Dr.
principal investigator · McMaster University, Department of Family Medicine

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion